Gland Pharma shares surged after strong Q1 results and positive commentary from brokerages citing a turnaround at its European unit Cenexi. EBITDA margins expanded to 24.4%, and net profit rose 50% YoY. Despite weak U.S. sales, growth in Europe and new launches supported the outlook. Brokerages raised earnings estimates and targets, expecting further gains as Cenexi scales profitability.
13 BSE 500 stocks surged up to 200% in just 3 months; 3 turned multibaggers
Despite volatile markets, several stocks delivered exceptional returns, with 13 companies gaining 70–200% in three months. HFCL led the rally, while broader market strength created
June 25, 2026